Replies to post #187061 on Biotech Values

[DewDiligence]

PFE-HSP CC slides:

http://t.co/PqlTUr9wFL

[DewDiligence]

(PFE/HSP)—S&P pharma analyst, Jeffrey Loo must be pretty sharp—he just upgraded HSP from Strong Sell to Hold:

http://blogs.barrons.com/stockstowatchtoday/2015/02/05/pfizer-climbs-on-hospira-acquisition

LMAO

[Bio_Tech_Boss]

Just saw 13g, they also own 4.8% up ESPR

[DewDiligence]

HSP shareholders approve PFE buyout at $90/sh:

http://finance.yahoo.com/news/hospira-shareholders-approve-merger-hospira-174000478.html

It seems superfluous to have a vote by shareholders of the acquired company in an all-cash deal, but this was a condition of the deal.

[DewDiligence]

PFE closes HSP acquisition:

http://finance.yahoo.com/news/pfizer-completes-acquisition-hospira-130000829.html

Pfizer continues to expect the transaction to be immediately accretive to adjusted diluted EPS1 upon closing, and accretive by $0.10 - $0.12 per share in the first full year after the close, with additional accretion anticipated thereafter. In addition, Pfizer expects the transaction will deliver $800 million in annual cost synergies by 2018.

Pfizer intends to update its 2015 financial guidance in the coming weeks to incorporate Hospira.

[DewDiligence]

PFE exploring divestment of Hospira hospital business:

https://finance.yahoo.com/news/exclusive-pfizer-explores-sale-hospital-144728674.html

The unit could fetch “a few billion” dollars, according to Reuters sources.